Calyx Therapeutics, Inc.

Anergen, Inc.

Bexel Pharmaceuticals, Inc.

Theracos, Inc.

Renovel Innovations, Inc.

Corixa Corporation

Katra Phytochem (india) Private Limited

Kerala Ayurveda Limited (india)

Natpro, Inc.

Bishwajit Nag

Debendranath Dey

Partha Neogi

Satyanarayana Medicherla

Somesh D Sharma

Ananda Sen

Nitish Nag

Arjun Sanyal

Srinivasan Narasimhan

Abhijeet Nag

Shiv Kumar Agarwal

Subramaniam Sriram

Brian R Clark

Frederick J Lakner

John Bright

Surendra Kumar Pandey

Abjiheet Nag

Gaddam Om Reddy

Harden M McConnell

Arthur Lee

Satyanarayana Medicheria

Bindu Pandey

Anil B Ray

Eric T Rhodes

Birendra Kumar Bhattacharya

Sangamesh Badiger

Prabha V Mukku

Gajendra Singh

Teresa Kendrick

Jai P Chansouria

Debendranath Dev

Vinod Kumar Singh

Santhanagopalan Chithra

Patanjali Subramoni

Preeti Balse

Sundaram Chandrasekharan

Jayashree Madhavan

Surendradoss Jayakumar

Anilkumar K

Sarala Samuel

Ramesh Vangal

Sujata Neogi

Jayarajan Kodikannath

Para-acyl substituted diazacyclohexenes, medical formulations thereof and methods for making and using the same.

Acyloxy substituted phenyl dithiane derivatives

Novel Halogenated Benzylidine derivatives are provided which exhibit activity for the treatment of immunological diseases and inflammation.

Halogenated benzylidene derivatives

Para acyl substituted diazacyclohexene derivatives

Novel Styryl Carboxylate derivatives are provided which exhibit activity for the treatment of immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, neurological diseases, and diabetes.

Styryl carboxylate derivatives

The present invention generally relates to an herbal composition effective in management of disorders related to metabolic syndrome. More particularly, the invention relates to an herbal composition effective in the management of disorders related to metabolic syndrome such as Type 2 diabetes mellitus, obesity and lipid profile management and a process for the preparation of such an herbal composition. The invention further relates to the use of the herbal composition in preparation of food supplements, pharmaceuticals and nutraceuticals for the management of disorders related to metabolic syndrome. The herbal composition effective in management of metabolic syndrome related disorders comprises of herbs selected from-and. Also provided is the use of herbal composition for the treatment of disorders related to metabolic syndrome. Also provided is a method of treating disorders related to metabolic syndrome comprising administering to a subject in need thereof a therapeutically effective amount of the herbal composition of the present invention.

Herbal composition

The present invention relates to novel heterocyclic diphenyl ether and diphenyl amine compounds, derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and pharmaceutically acceptable solvates thereof and pharmaceutically acceptable compositions containing these singly or in combination. The compounds of the present invention are effective in lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels and are useful in the treatment and/or prophylaxis of diabetes. The compounds of the present invention are effective in treatment of obesity, inflammation, autoimmune diseases such as multiple sclerosis and rheumatoid arthritis and immunological diseases, including the treatment of cancer. Furthermore, the compounds are useful for the treatment of disorders associated with insulin resistance.

Heterocyclic diphenyl ethers

Novel dipeptide ethers are effective for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels. The dipeptide ethers are also useful for the treatment and/or prophylaxis of diabetes, obesity, inflammation and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

Dipeptide phenyl ethers

Novel diphenyl ether derivatives are provided that exhibit activity useful for reducing glucose, cholesterol, and/or triglyceride levels in plasma, and for treatment of obesity, inflammation, immunological diseases, autoimmune diseases, diabetes and disorders associated with insulin resistance.

Diphenyl ether derivatives

Novel hydroxamic acid containing amino acid derivatives are provided that are useful for treatment of inflammation, inflammatory and immunological diseases; lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; and for treatment or prophylaxis of metabolic disorders.

Hydroxamic acid-containing amino acid derivatives

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

Heterocyclic analogs of diphenylethylene compounds

Novel amino acid derivatives are provided that are useful for management of disorders such as obesity and immunological diseases. The derivatives are also useful in lowering blood glucose levels in hyperglycemic disorders and for treating related disorders such as body weight gain, elevated free fatty acid, cholesterol and triglyceride levels and other disorder exacerbated by obesity.

Derivatives of amino acids for treatment of obesity and related disorders

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. In contrast to previously reported thiazolidinedione compounds, known to lower leptin levels, the present compounds increase leptin levels and have no known liver toxicity. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

Growing community of inventors

Union City, CA, United States of America

Bishwajit Nag